Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).
Brief Summary: The primary objectives of this study are:

* To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD);
* To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.


Options:
A: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg
B: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: A3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A4; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): A2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A3 | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): A4
C: Arm Label: Edoxaban Regimen; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Clopidogrel, Drug: Prasugrel, Drug: Ticagrelor | Arm Label: Vitamin K Antagonist Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Prasugrel, Drug: Ticagrelor, Drug: Vitamin K antagonist | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban Regimen | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Edoxaban Regimen, Vitamin K Antagonist Regimen | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Edoxaban Regimen, Vitamin K Antagonist Regimen | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Edoxaban Regimen, Vitamin K Antagonist Regimen | Intervention Type: DRUG; Name: Vitamin K antagonist; Assigned to Arm(s): Vitamin K Antagonist Regimen
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2

Answer: A